
APPOINTMENT OF DIRECTOR & APPENDIX 3X

Highlights

- Mr. Aaron Brinkworth appointed an independent Non-executive Director of the Company.
- Employed by Gilead Sciences, Inc. (Nasdaq: GILD) for 22 years, from 1998-2020, in senior commercial, patient access and licensing roles – including heading the Asia Pacific Region (Global Patient Solutions), covering 31 countries across the APAC.
- Gilead is focussed on treatment of liver related diseases and HIV/AIDS.
- Mr Brinkworth’s pharma industry and clinical contacts will be invaluable as the Company progresses its MRI liver fibrosis project and pursues early commercialisation opportunities.

Resonance Health Ltd (ASX: RHT) (**Resonance Health or Company**) advises that Mr. Aaron Brinkworth has been appointed a Non-executive Director of the Company.

Appointment of Director

Mr. Brinkworth had a 22-year career with US headquartered, Nasdaq listed, Gilead Sciences, Inc. (Nasdaq: GILD) (**Gilead**). During this time the company grew from a small biotech-pharmaceutical company to a multi-billion-dollar global pharmaceutical company with annual sales of over USD \$27 billion.

During his career at Gilead, Mr. Brinkworth held several commercial, licensing, and patient access roles, including that of Executive Director - Gilead Sciences Global Patient Solutions, where he was responsible for developing and implementing comprehensive commercial and access strategies for emerging markets. He led Gilead’s commercial and access operations in the Asia Pacific (**APAC**) where he was responsible for Gilead’s branded product business, managing a geographically dispersed team and partners across 31 APAC countries including China, India, and Vietnam.

During Mr. Brinkworth’s career with Gilead, he completed their Senior Leadership Development Program and was recognised with multiple awards. Mr. Brinkworth has a Bachelor’s degree in Health Sciences from Edith Cowan University, and he has served on the Board of Directors of the Royal Surf Lifesaving Society of Western Australia since 2020. He is a graduate of the AICD Company Directors course and maintains active membership of the AICD.

The Board considers Mr. Brinkworth to be independent for the purposes of the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations.

Resonance Health Managing Director, Mitchell Wells said:

“With his stellar career in the large international pharma industry, Aaron is a welcome and invaluable addition to Resonance Health’s Board of Directors. His strategic insights, pharma industry and medical relationships, and focus on commercial outcomes will be indispensable for the Company as it continues to deliver on its core focus - developing and deploying non-invasive medical imaging biomarkers for use by doctors and pharmas, as they tackle the enormous human, societal and economic challenges of chronic liver and liver-related disease.

Aaron’s pharma industry and clinical contacts will be vital as the Company progresses its MRI liver fibrosis project – a key strategic priority for the company - and pursues early commercialisation opportunities with large

pharma companies that are undertaking the many chronic liver disease clinical drug trials currently underway and planned.”

Commenting on his appointment, Mr. Brinkworth said:

“I’m excited by the opportunity to join Resonance Health’s Board of Directors and the contribution I can make to the Company achieving its strategic priorities – and, in particular, its MRI liver fibrosis project.

Liver fibrosis plays a central role in the progression of chronic liver disease. An accurate, non-invasive, biomarker for liver fibrosis is a recognised unmet need that is being championed by the FDA and other regulators, as well as being highly sought after by large pharmas actively pursuing drug development for chronic liver disease.”

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd.

For further information please contact:

Mitchell Wells – Managing Director
E: mitchellw@resonancehealth.com
P: +61 (0)8 9286 5300

Nick Allan – Chief Operating Officer
E: nicholasa@resonancehealth.com
P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company’s services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-assisted, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®.
- **HepaFat-Scan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFat-AI®**, an AI-assisted, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-assisted, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis.

Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter.

FOLLOW US



/Resonance-Health-Ltd



/ResonanceHealth



/ResonanceHealthLtd

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: Resonance Health Ltd
ABN 96 006 762 492

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Aaron Brinkworth
Date of appointment	27 March 2023

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil.

+ See chapter 19 for defined terms.

Appendix 3X Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest.	Nil.

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	None.
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.